Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 17Genitourinary 2Tumor-Agnostic 1Other 1Classical hematology 1

Conditions

Prostatic Neoplasms 2Osteoporosis 1Hot Flashes 1Anemia 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Estradiol × Genitourinary × Clear all
NCT07466498 2026-03-12

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

University of Washington

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT00303784 2020-11-27

PATCH

University College, London

Phase 3 Unknown
2,200 enrolled
Classical hematologyGenitourinary

Anemia, Osteoporosis, Prostatic Neoplasms, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡